Welcome to our dedicated page for Neurometrix SEC filings (Ticker: NURO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Neurometrix's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Neurometrix's regulatory disclosures and financial reporting.
NeuroMetrix, Inc. Schedule 13G/A (Amendment No. 2) discloses that The Radoff Family Foundation and Bradley L. Radoff no longer beneficially own any common stock of the company. As of the close of business on June 30, 2025, both Reporting Persons report 0 shares and 0% ownership of the class, indicating they hold no voting or dispositive power over NeuroMetrix shares.
The filing identifies the reporting entities, their principal address and citizenship, confirms the disclosure covers common stock with $0.0001 par value, and includes a certification that the securities were not acquired to influence control of the issuer.